56,844 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by Tema Etfs LLC

Tema Etfs LLC purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 56,844 shares of the company's stock, valued at approximately $1,987,000.

Several other institutional investors and hedge funds have also recently modified their holdings of IONS. Silvercrest Asset Management Group LLC bought a new position in shares of Ionis Pharmaceuticals in the fourth quarter worth approximately $231,000. Rafferty Asset Management LLC increased its holdings in shares of Ionis Pharmaceuticals by 19.4% in the 4th quarter. Rafferty Asset Management LLC now owns 237,337 shares of the company's stock worth $8,297,000 after buying an additional 38,578 shares during the last quarter. Raiffeisen Bank International AG purchased a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at $62,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Ionis Pharmaceuticals by 63.9% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 60,580 shares of the company's stock worth $2,118,000 after acquiring an additional 23,623 shares during the last quarter. Finally, Orbimed Advisors LLC grew its position in Ionis Pharmaceuticals by 21.2% in the fourth quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company's stock worth $98,494,000 after acquiring an additional 492,900 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company's stock.

Insider Transactions at Ionis Pharmaceuticals

In related news, Director Michael R. Hayden bought 15,000 shares of the company's stock in a transaction on Thursday, May 1st. The shares were acquired at an average cost of $31.86 per share, with a total value of $477,900.00. Following the completion of the acquisition, the director now owns 50,219 shares of the company's stock, valued at $1,599,977.34. The trade was a 42.59% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.60% of the company's stock.

Ionis Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ IONS traded down $0.59 during trading hours on Friday, hitting $32.67. The company's stock had a trading volume of 403,237 shares, compared to its average volume of 1,544,302. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $52.34. The stock has a market cap of $5.20 billion, a price-to-earnings ratio of -10.74 and a beta of 0.15. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The business has a 50-day simple moving average of $30.59 and a 200-day simple moving average of $33.11.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.14. The firm had revenue of $132.00 million for the quarter, compared to analyst estimates of $144.31 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The business's quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the company earned ($0.98) EPS. On average, analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IONS. Redburn Atlantic started coverage on Ionis Pharmaceuticals in a research report on Monday, March 31st. They set a "neutral" rating and a $39.00 price target on the stock. JPMorgan Chase & Co. decreased their price objective on Ionis Pharmaceuticals from $47.00 to $45.00 and set a "neutral" rating on the stock in a report on Monday, March 24th. BMO Capital Markets dropped their target price on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research report on Thursday, February 20th. Citigroup reduced their price target on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Finally, Wall Street Zen raised shares of Ionis Pharmaceuticals to a "sell" rating in a research note on Tuesday, March 18th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.67.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.